New York Times July 17, 2025: This FDA panel hosted by Commissioner Makary ignores evidence of the serious risks of hormone therapy for menopause, such as breast cancer, endometrial cancer, and stroke. Instead it focuses only on benefits, relying on misleading and erroneous information. The panel wants to remove the “black box” warning that tells women about the risks. No public comment was allowed at the meeting. We would have disagreed strongly, except with the issue of whether hormonal cream used in the vagina should not have the same black box warning as the hormonal pills.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
MIT Technology Review: Meet Jim O’Neill, the longevity enthusiast who is now RFK Jr.’s right-hand man
MIT Technology Review July 1, 2025: HHS Deputy Secretary Jim O’Neill wants unproven medical treatments to be very widely available and HHS to focus funding on longevity research so that those who can afford them can live much longer. This could include areas at sea or in states that are not subject to FDA safeguards. What will happen to the millions of Americans who need healthcare for diseases they already have?
Read More »RFK Jr.’s tough talk on corporate influence isn’t adding up in practice
Environmental Health Network, June 26, 2025: EHN reports that HHS and RFK Jr. claim to stop conflicts of interest, but industry influence and other conflicts remain, as explained by NCHR’s Diana Zuckerman.
Read More »RFK Jr.’s Planned Assault on Corporate Influence Is Clashing With Reality
NOTUS News, June 26, 2025: NOTUS news article gives numerous examples from experts who agree with RFK Jr and Makary criticisms of corporate influence on health, but say HHS plans to reduce conflicts of interest are ineffective and FDA remains overly influenced by industry.
Read More »Biotech pauses trial after second patient death linked to gene therapy
The Washington Post, June 17, 2025; Sarepta restricts Elevidys gene therapy for non-ambulatory Duchenne muscular dystrophy patients after second death. We point out that FDA flexibility “does no favor” to patients who may die from using a questionable treatment. Elevidys costs $3.2 million per patient.
Read More »